Stock Research for PTLA

PTLA

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

PTLA Stock Chart & Research Data

The PTLA chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PTLA chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PTLA Due diligence Resources & Stock Charts

The PTLA stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PTLA Detailed Price Forecast - CNN Money CNN View PTLA Detailed Summary - Google Finance
Yahoo View PTLA Detailed Summary - Yahoo! Finance Zacks View PTLA Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View PTLA Trends & Analysis - Trade-Ideas Barrons View PTLA Major Holders - Barrons
NASDAQ View PTLA Call Transcripts - NASDAQ Seeking View PTLA Breaking News & Analysis - Seeking Alpha
Spotlight View PTLA Annual Report - CompanySpotlight.com OTC Report View PTLA OTC Short Report - OTCShortReport.com
TradeKing View PTLA Fundamentals - TradeKing Charts View PTLA SEC Filings - Bar Chart
WSJ View Historical Prices for PTLA - The WSJ Morningstar View Performance/Total Return for PTLA - Morningstar
MarketWatch View the Analyst Estimates for PTLA - MarketWatch CNBC View the Earnings History for PTLA - CNBC
StockMarketWatch View the PTLA Earnings - StockMarketWatch MacroAxis View PTLA Buy or Sell Recommendations - MacroAxis
Bullish View the PTLA Bullish Patterns - American Bulls Short Pains View PTLA Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View PTLA Stock Mentions - StockTwits PennyStocks View PTLA Stock Mentions - PennyStockTweets
Twitter View PTLA Stock Mentions - Twitter Invest Hub View PTLA Investment Forum News - Investor Hub
Yahoo View PTLA Stock Mentions - Yahoo! Message Board Seeking Alpha View PTLA Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for PTLA - SECform4.com Insider Cow View Insider Transactions for PTLA - Insider Cow
CNBC View PTLA Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PTLA - OTC Markets
Yahoo View Insider Transactions for PTLA - Yahoo! Finance NASDAQ View Institutional Holdings for PTLA - NASDAQ


Stock Charts

FinViz View PTLA Stock Insight & Charts - FinViz.com StockCharts View PTLA Investment Charts - StockCharts.com
BarChart View PTLA Stock Overview & Charts - BarChart Trading View View PTLA User Generated Charts - Trading View




Latest Financial News for PTLA


See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
Posted on Tuesday January 15, 2019

# Portola Pharmaceuticals Inc ### NASDAQ/NGS:PTLA View full report here! ## Summary * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is extremely high for PTLA with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting PTLA. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $3.05 billion over the last one-month into ETFs that hold PTLA are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.


Why Portola Pharmaceuticals Rose 8.09% on January 4
Posted on Monday January 07, 2019

Why Portola Pharmaceuticals Rose 8.09% on January 4 ## Stock performance On January 4, Portola Pharmaceuticals stock closed at $19.38, an 8.09% increase from its prior close of $17.93 on January 3. On December 31, 2018, Portola Pharmaceuticals stock price grew ~14.22% to reach $19.52 from its prior close of $17.09 on December 28. The stock price on January 4 was ~65% below its 52-week high of $55.48 on January 29, 2018. The company hit its 52-week low of $14.81 on December 24, 2018. ## Recent developments On December 2018, the US FDA (Food and Drug Administration) approved Portola Pharmaceuticals’ PAS (prior approval supplement) for large-scale, second-generation Andexxa. The approval enables a wide commercial launch of Andexxa in the US market. In May 2018, the FDA approved Andexxa under the accelerated approval pathway. The FDA also granted Andexxa an orphan drug designation and a breakthrough therapy designation. The approval is expected to boost the commercial launch of Andexxa in the US market, which in turn could significantly boost the revenue growth of Portola in 2019. ## Financials in a nutshell In the first nine months of 2018, Portola Pharmaceuticals’ net revenues grew ~95% YoY to reach $24.8 million from $12.7 million. Wall Street analysts estimate that Portola Pharmaceuticals will generate net revenues of $35.70 million, which represents ~58.35% YoY growth. The revenue growth of Portola Pharmaceuticals (PTLA) could boost the SPDR S&P Biotech ETF (XBI). The company makes up about ~1.31% of XBI’s total portfolio holdings. In the first nine months of 2018, Portola reported net income and EPS of -$261.7 million and -$3.97, respectively, compared to -$194.3 million and -$3.38 in the same period the prior year. Wall Street analysts estimate that Portola Pharmaceuticals will report net income and EPS of -$333.57 million and -$5.03, respectively, in fiscal 2018. ## Analysts’ recommendations Of the seven analysts tracking Portola Pharmaceuticals in January 2019, three of them recommended a “strong buy,” two analysts recommended a “buy” rating, and two analysts recommended a “hold” rating. On January 7, 2019, the company had a consensus 12-month target price of $35.83, which represents a ~84.88% return on investment over the next 12 months.


Take Profits on This Pharma Stock
Posted on Thursday January 03, 2019

PTLA stock rallied more than 14% on Monday on a regulatory win


Portola Up as Large-Scale Andexxa Production Gets FDA Nod
Posted on Wednesday January 02, 2019

Portola Pharmaceuticals (PTLA) announces FDA approval for large-scale Generation II manufacturing process for Andexxa to support commercial launch expected this month.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.